The U.S. Preventive Services Task Force recommends individualized decision making, not blanked against prostate-specific antigen (PSA) screening for prostate cancer, but the incidence of metastatic prostate cancer has been increasing rapidly since 2012 (2). Here, KLK3 is linked to metastatic prostate carcinoma.